男性下尿路症状（LUTS）怎么治？保守+药物治疗全说透
不少成年男性都被下尿路症状（LUTS）困扰，尿频尿急、排尿不畅这些问题，真的特别影响日常生活和睡眠。根据2025版EAU非神经源性男性LUTS指南[1]，管理这种症状主要分保守治疗、药物治疗和手术治疗，今天就用通俗的话给大家梳理保守和药物治疗的关键知识点，都是临床验证过的实用建议，照着参考准没错。
保守治疗是所有干预的基础，尤其适合症状比较轻、没太影响生活的人。核心思路就是通过调整生活习惯、密切观察，不用一上来就吃药做手术[2]。
说实在的，很多轻度LUTS患者不用急着用药，观察等待就够了。只要症状没影响到工作、睡眠，也没有肾功能损伤、尿潴留这些风险[3]，就可以先观察。有研究显示，大概85%的轻度患者，1年里病情都不会进展，只有15%可能因为症状加重需要进一步治疗[4]。
但观察等待绝对不是“不管了”，建议6个月先去复查一次，之后每年查一次，看看症状有没有变化，做个IPSS评分、尿流率这些检查[5]。如果发现症状越来越重，比如夜尿次数变多，或者残余尿量增加，就说明观察等待可能不管用了，得赶紧调整方案[6]。
这部分是保守治疗的关键，很多人通过调整习惯，症状就能明显改善。
饮水方面，睡前两三个小时就别喝太多水了，不然夜尿会特别频繁；还有咖啡、酒精、碳酸饮料这些，容易刺激膀胱黏膜，加重尿频尿急，能少喝就少喝[7]。排尿的时候可以试试“双重排尿”，排完等一会儿再排一次，能减少残余尿量，避免排尿后滴沥的情况；平时也可以练一练主动有意识的用力膀胱收缩，排空残余尿量，缓解滴沥问题[8]。
如果经常感觉尿急，试试分散注意力，比如深呼吸、放松盆底肌，慢慢延长排尿间隔，这样能逐渐增加膀胱容量[9]。另外，便秘也会压迫前列腺和膀胱，加重梗阻，得积极处理；还有正在吃的药，比如有些抗抑郁药、利尿剂，可能会让LUTS更严重，最好咨询医生能不能调整[10]。
值得一提的是，有随机对照试验显示，在单纯观察的基础上，多接受3次自我管理指导（比如教你怎么调整饮食、怎么排尿），患者的症状改善会明显更好，生活质量也会提升[11]。
目前还没有研究单独验证过某一种调整方式（比如只控制饮水、只做膀胱训练）的效果，现有证据大多是综合干预的结果[12]。所以实际调整的时候，得结合自己的情况，比如有没有糖尿病、高血压这些基础病，个性化制定方案，而且一定要长期坚持才有用[13]。
如果保守治疗试了一段时间，症状还是没改善，或者已经明显影响生活了，就该考虑药物治疗了。指南里强调，用药得看症状类型（是尿频尿急为主，还是排尿困难为主）、前列腺大小、有没有其他毛病这些因素[14]，不能盲目吃。
这类药是缓解LUTS的“主力军”，起效特别快。它能抑制前列腺和膀胱颈部的平滑肌收缩，降低尿道阻力，所以排尿困难、尿流慢这些问题能很快缓解；有些药还能作用于膀胱逼尿肌，对尿频尿急也有帮助[15]。
常用的有阿夫唑嗪、多沙唑嗪、坦索罗辛、西洛多辛这些，不同制剂的疗效差不多，主要是不良反应不一样[16]。一般吃药后几小时到几天就有效果，长期用下来，IPSS评分能降30%-40%，最大尿流率也能提升20%-25%[17]。前列腺体积小于40mL的患者，长期用效果更稳定；就算前列腺大，也能快速缓解症状[18]。
不过不良反应得注意，比如头晕、乏力、体位性低血压，多沙唑嗪、特拉唑嗪的血管扩张作用比较明显，年纪大的或者有心血管病的患者要慎用[19]；西洛多辛、坦索罗辛对前列腺的针对性强，低血压风险低，但可能会影响射精，比如逆行射精、精液减少，年轻还在意性功能的患者，用药前得知道这一点[20]。另外，如果之后要做白内障手术，一定要提前告诉眼科医生，避免术中出现“术中虹膜松弛综合征（简称IFIS）”[21]。
这类药和α1受体拮抗剂不一样，它是通过抑制睾酮转化为双氢睾酮，让前列腺上皮细胞凋亡，长期用能让前列腺体积缩小18%-28%，从根源上缓解梗阻[22]。
常用的有非那雄胺和度他雄胺，两者疗效差不多，度他雄胺让前列腺缩小的速度稍微快一点[23]。适合那些症状中度到重度，而且前列腺体积超过40mL、PSA水平高于1.4-1.6ng/mL的患者[24]。
但它起效比较慢，得连续吃6个月以上才能达到最好效果，长期用（2-4年）能让IPSS评分降15%-30%，最大尿流率提升1.5-2.0mL/s[25]。最大的好处是能减少疾病进展的风险，比如降低急性尿潴留和前列腺相关手术的需求，相对风险能降57%-68%[26]。
不良反应主要影响性功能，比如性欲减退、勃起功能障碍、射精异常，发生率大概5%-10%，停药后大多能慢慢恢复[27]；长期用可能会轻微增加高分级前列腺癌的检出风险，用药前医生会和你充分沟通[28]。
如果主要困扰是尿频、尿急、急迫性尿失禁这些储存症状，不管有没有前列腺增生，都可以用这类药[31]。它能阻断膀胱逼尿肌的M受体，抑制逼尿肌过度活动，从而缓解这些症状[29]。
常用的有托特罗定、索利那新、奥昔布宁这些，还有奥昔布宁贴剂这种透皮制剂，能减少口服药带来的口干副作用[30]。单独用的话，尿急次数能减少30%-40%，白天排尿次数也能少1-2次[32]。
但要注意，残余尿量超过150mL的患者别用，不然可能会增加尿潴留的风险[33]。常见的不良反应是口干（发生率10%-16%）、便秘（3%-4%），大多是轻度到中度，用久了就能耐受[34]。
这类药比较温和，能激活膀胱逼尿肌的β3受体，让逼尿肌松弛，增加膀胱容量，减少尿频尿急，还不影响排尿功能[35]。目前常用的是米拉贝隆，适合以储存症状为主的患者[36]。
它最大的优势就是口干、便秘这些副作用比毒蕈碱受体拮抗剂少多了，适合那些受不了抗胆碱能药物副作用的患者[37]；如果和α1受体拮抗剂一起用，对既有梗阻又有储存症状的混合性LUTS，效果会更好[38]。用药期间要监测血压，严重高血压患者（收缩压≥180mmHg或舒张压≥110mmHg）不能用[39]。
如果不仅有LUTS，还合并勃起功能障碍（ED），选这类药就很合适，能同时改善两个问题[42]。它通过抑制磷酸二酯酶5，增加膀胱、前列腺和尿道的血流量，放松平滑肌，从而改善症状[40]。
目前只有他达拉非（5mg每日一次）获批用于LUTS治疗，其他像西地那非、伐地那非，虽然有研究说对LUTS有效，但还没获批这个适应症[41]。用下来能让IPSS评分降1.8-2.0分，对夜尿、排尿困难都有帮助，但提升最大尿流率的效果不如α1受体拮抗剂[43]；长期用1年，疗效也很稳定[44]。
特别提醒：绝对不能和硝酸酯类药物（比如硝酸甘油）一起用，会导致严重低血压；有严重心血管病（比如近期心肌梗死、心力衰竭）的患者也不能用[45]。
指南里只认可锯棕榈提取物（Serenoa repens），尤其是己烷提取的锯棕榈提取物（HESr），证据最充分[46]。它能改善夜尿次数，平均能少0.64次/夜，最大尿流率也能提升2.75mL/s，疗效和α1受体拮抗剂差不多，但起效慢，得连续用3-6个月[47]。
最大的好处就是对性功能几乎没影响，适合那些担心药物影响性生活的患者；不良反应主要是胃肠道不适，发生率大概3.8%，耐受性很好[48]。不过要注意，植物提取物的质量和提取工艺关系很大，得选正规厂家的产品；而且要知道它的疗效可能比化学药物稍微弱一点，别抱有太高期望[49]。
如果症状比较重，单一药物效果不够，就可以考虑联合治疗。
比如α1受体拮抗剂+5α还原酶抑制剂，适合前列腺体积超过40mL、症状中重度，还担心病情进展的患者[50]。α1受体拮抗剂快速缓解症状，5α还原酶抑制剂长期缩小前列腺，一起用不仅症状改善更明显，还能显著降低尿潴留和手术的风险[51]。建议至少用12个月，症状稳定后，医生可能会建议慢慢停用α1受体拮抗剂，只留5α还原酶抑制剂维持[52]。
如果是既有梗阻又有储存症状，单独用α1受体拮抗剂后尿频尿急还没好，就可以加用毒蕈碱受体拮抗剂或β3受体激动剂[53]。联合用能让储存症状再降20%-30%，但一定要监测残余尿量，别超过150mL[54]。
还有α1受体拮抗剂+PDE5Is，适合中重度LUTS合并ED的患者，不仅能同时改善两个问题，最大尿流率的提升也比单独用α1受体拮抗剂好[55]，不良反应也没明显增加，耐受性不错[56]。
参考文献（上下滑动查看）：
[1] Cornu JN, Gacci M, Hashim H, et al. EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS) 2025. Eur Urol, 2025.
[2] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn, 2002, 21(2):167-178.
[3] Nickel JC, Gilling P, Tammela TL, et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract, 2008, 62(10):1547-1556.
[4] Netto NR Jr, de Sousa TA, da Silva Filho AG, et al. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology, 1999, 53(2):314-318.
[5] Flanigan RC, Wasson JH, Ruthazer R, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol, 1998, 160(1):12-17.
[6] McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349(24):2387-2398.
[7] Brown CT, Abrams P, Moore KN, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ, 2007, 334(7587):25.
[8] Yap TL, Abrams P, Moore KN, et al. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int, 2009, 104(6):1104-1109.
[9] Albarqouni L, Moore KN, Brown CT, et al. Self-Management for Men With Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis. Ann Fam Med, 2021, 19(2):157-165.
[10] Brown CT, Abrams P, Cardozo L, et al. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol, 2004, 46(2):254-259.
[11] Michel MC, Vauquelin G, Van der Aa L, et al. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 2006, 147(Suppl 2):S88-S100.
[12] Kortmann BB, Michel MC, Oelke M. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology, 2003, 62(1):1-8.
[13] Barendrecht MM, Michel MC, Oelke M. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn, 2008, 27(3):226-232.
[14] Djavan B, Marberger MJ, Oelke M, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology, 2004, 64(6):1081-1088.
[15] Michel MC, Oelke M, Stief CG. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis, 1998, 1(4):332-336.
[16] Fusco F, Novara G, Ficarra V, et al. alpha1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol, 2016, 69(6):1091-1099.
[17] Boyle P, Roehrborn CG, Andriole GL, et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology, 2001, 58(4):717-724.
[18] Roehrborn CG. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis, 2006, 9(2):121-125.
[19] Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol, 2008, 179(2):616-621.
[20] Gacci M, Corona G, Jannini EA, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med, 2014, 11(7):1554-1568.
[21] Chatziralli IP, Kourtis A, Nikolopoulos K, et al. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology, 2011, 118(4):730-737.
[22] Andriole GL, Bostwick DG, Brawley OW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol, 2004, 172(4 Pt 1):1399-1403.
[23] Rittmaster RS, Hamdy FC, Shapiro E, et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab, 1996, 81(3):814-820.
[24] Naslund MJ, Andriole GL, Brawley OW, et al. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther, 2007, 29(1):17-34.
[25] Andersen JT, Lauritzen C, Rasmussen SE, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology, 1995, 46(4):631-636.
[26] Kirby RS, Roehrborn CG, McConnell JD, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 2003, 61(1):119-125.
[27] Corona G, Rastrelli G, Monami M, et al. Sexual dysfunction in subjects treated with inhibitors of 5alpha-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology, 2017, 5(4):671-681.
[28] Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med, 2010, 362(15):1192-1202.
[29] Chess-Williams R, Bello AK, Fryer RM. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol, 2001, 21(4):243-250.
[30] Matsui M, Yamada S, Hatazawa R, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A, 2000, 97(19):9579-9584.
[31] Chapple CR, Cardozo L, Khullar V, et al. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol, 2006, 49(4):651-661.
[32] Michel MC, Oelke M, Stief CG. Does gender or age affect the efficacy and safety of tolterodine? J Urol, 2002, 168(3):1027-1032.
[33] Chapple C, Abrams P, Cardozo L, et al. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Curr Med Res Opin, 2015, 31(7):1201-1214.
[34] Dmochowski R, Appell RA, Chapple CR, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol, 2007, 51(6):1054-1062.
[35] Andersson KE. On the Site and Mechanism of Action of beta3-Adrenoceptor Agonists in the Bladder. Int Neurourol J, 2017, 21(1):6-12.
[36] Chapple CR, Khullar V, Nitti VW, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 2013, 63(2):296-304.
[37] Herschorn S, Shapiro E, Nitti VW, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology, 2013, 82(2):313-320.
[38] Kakizaki H, Ichihara K, Fujimoto K, et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus, 2020, 6(4):729-736.
[39] White WB, Gomm W, Chapple CR, et al. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens, 2018, 12(5):768-778.
[40] Giuliano F, Vignozzi L, Filippi S, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol, 2013, 63(3):506-515.
[41] Pattanaik S, Guo B, Sebastianelli A, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev, 2018, 11(11):CD010060.
[42] Guo B, Pattanaik S, Sebastianelli A, et al. Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. Med Sci Monit, 2020, 26:e923179.
[43] Gacci M, Corona G, Jannini EA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2012, 61(6):994-1004.
[44] Wang Y, Zhang Y, Liu J, et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms, 2018, 10(2):84-91.
[45] EMA. Tadalafil Lilly : EPAR - Product Information. EMA, 2017. EMEA/H/C/004666 - R/0008.
[46] Committee on Herbal Medicinal Products. European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus. EMA/HMPC/280079/2013, 2015.
[47] Novara G, Morgia G, Ficarra V, et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2016, 2(6):553-562.
[48] Vela-Navarrete R, Carballo J, Castiella A, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R))) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int, 2018, 122(6):1049-1059.
[49] Russo GI, Morgia G, Novara G, et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus, 2020, 7(3):420-430.
[50] McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349(24):2387-2398.
[51] Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010, 57(1):123-131.
[52] Barkin J, Roehrborn CG, Siami P, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol, 2003, 44(4):461-466.
[53] Kaplan SA, Wein AJ, Kavoussi LR, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA, 2006, 296(19):2319-2328.
[54] Lenfant L, Drai J, Traxer O, et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol, 2023, 209(2):314-322.
[55] Tu YK, Chen PC, Lin HC, et al. Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha-blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis. Urological Science, 2020, 31(3):99-106.
[56] Sebastianelli A, Novara G, Ficarra V, et al. Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. Minerva Urol Nephrol, 2021, 73(6):836-843.
声明：本内容仅供医学药学专业人士阅读，不构成实际治疗建议。转载请后台联系授权，侵权必究！ 编辑：吴梦霞 审核：黄鹏程